Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | TSHR | P16473 | 7/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793900 | 0.95 | ALDH1A1 (0.51) | CYP2C19HIF1AALDH1A1TSHRALOX15 | |
| SCHEMBL2712904 | 0.90 | TDP1 (0.53) | CYP2C19HIF1AALDH1A1TSHRTDP1 | |
| SCHEMBL27625176 | 0.89 | TDP1 (0.51) | CYP2C19HIF1AALDH1A1TSHRTDP1 | |
| SCHEMBL3485285 | 0.89 | TDP1 (0.51) | CYP2C19HIF1AALDH1A1TSHRTDP1 | |
| SCHEMBL6663875 | 0.89 | L3MBTL1 (0.44) | CYP2C19HIF1ATSHRTDP1NPC1 | |
| SCHEMBL6664530 | 0.86 | NPC1 (0.47) | ALDH1A1NPC1L3MBTL1TP53NPSR1 | |
| SCHEMBL27993391 | 0.85 | ALDH1A1 (0.35) | CYP2C19HIF1AALDH1A1TSHRTDP1 | |
| SCHEMBL2071064 | 0.85 | TDP1 (0.47) | CYP2C19HIF1AALDH1A1TSHRTDP1 | |
| SCHEMBL1289443 | 0.84 | TDP1 (0.46) | CYP2C19HIF1AALDH1A1TSHRTDP1 | |
| SCHEMBL28075408 | 0.84 | TDP1 (0.46) | CYP2C19HIF1AALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113976059-B | Preparation process and equipment of cellulose citrate phthalate | 七星柠檬科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-113976059-A | Preparation process and equipment of cellulose citrate phthalate | 黄小燕 | 2022-01-28 | — | — | CN | claimed |
| WO-2014029953-A1 | HOT MELT EXTRUDED (HME) PHARMACEUTICAL COMPOSITION OF CINACALCET | CIPLA LIMITED (IN) | 2014-02-27 | — | — | WO | claimed |
| US-20100173921-A1 | Antiretroviral Solid Oral Composition | CIPLA LIMITED (IN) | 2010-07-08 | — | — | US | claimed |
| WO-2008017867-A2 | ANTIRETROVIRAL SOLID ORAL COMPOSITION WITH AT LEAST ONE WATER INSOLUBLE POLYMER | CIPLA LIMITED (IN) | 2008-02-14 | — | — | WO | claimed |
| CN-113976059-B | Preparation process and equipment of cellulose citrate phthalate | 七星柠檬科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-113976059-B | Preparation process and equipment of cellulose citrate phthalate | 七星柠檬科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023140729-A1 | ORAL DOSAGE FORMS OF A THERAPEUTICALLY ACTIVE ACID-LABILE SALT AND METHODS AND USES RELATED THERETO. | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-07-27 | — | — | WO | disclosed |
| EP-4212149-A1 | ORAL DOSAGE FORMS OF ACID-LABILE SALT AND METHODS AND USES RELATED THERETO | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-07-19 | — | — | EP | disclosed |
| CN-113976059-A | Preparation process and equipment of cellulose citrate phthalate | 黄小燕 | 2022-01-28 | — | — | CN | disclosed |
| CN-113976059-A | Preparation process and equipment of cellulose citrate phthalate | 黄小燕 | 2022-01-28 | — | — | CN | disclosed |
| CN-113976059-A | Preparation process and equipment of cellulose citrate phthalate | 黄小燕 | 2022-01-28 | — | — | CN | disclosed |
| WO-2009106824-A2 | PHARMACEUTICAL FORMULATIONS | CIPLA LIMITED (IN) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009087410-A2 | SOLID PHARMACEUTICAL DOSAGE FORM | CIPLA LIMITED (IN) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009081174-A2 | ANTI - RETROVIRAL COMBINATION | CIPLA LIMITED (IN) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009056818-A1 | NOVEL ANTIRETROVIRAL COMBINATION | CIPLA LIMITED (IN) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009016358-A2 | PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR MAKING THEM | CIPLA LIMITED (IN) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008017867-A2 | ANTIRETROVIRAL SOLID ORAL COMPOSITION WITH AT LEAST ONE WATER INSOLUBLE POLYMER | CIPLA LIMITED (IN) | 2008-02-14 | — | — | WO | disclosed |
| EP-1117387-A2 | COATED MEDICAMENT FORMS WITH CONTROLLED ACTIVE SUBSTANCE RELEASE | Röhm GmbH & Co. KG (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000019984-A2 | COATED MEDICAMENT FORMS WITH CONTROLLED ACTIVE SUBSTANCE RELEASE | RÖHM GMBH (DE) | 2000-04-13 | — | — | WO | disclosed |